MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.

2026-06-04 – Press Releases – www.prnewswire.com

SEOUL, South Korea, June 4, 2026 /PRNewswire/ — MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA’s agreement to conduct a single pivotal Phase 3 study for CARTISTEM® in the U.S. This milestone marks a…

Read the full article here.